Top 10 Primary Care Drugs Approved in Early 2017
Click through this slide summary for a look at some of the more significant approvals so far for primary care.
There’s always going to be the need for new medications, better medications.-Immunologist Anthony Fauci, MD
NIX NIGHTLY NOCTURIA: Noctiva (desmopressin acetate) Nasal Spray,
a vasopressin analog nasal spray indicated for nocturia resulting from nocturnal polyuria in adults, the first FDA-approved treatment for this condition. (Approved 3/3/17, Serenity Pharmaceuticals, LLC)
DIABETES COMBO: Qtern (dapagliflozin and saxagliptin) Tablets,
an SGLT2 inhibitor and DPP4 inhibitor fixed-dose combination indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes. (Approved 2/27/17, AstraZeneca Pharmaceuticals LP)
ASTHMA CORTICOSTEROIDS TIMES TWO
Two asthma medications for adolescent and adult patients delivered via Teva’s RespiClick® breath-activated, multi-dose dry powder inhaler:
AirDuo RespiClick (fluticasone propionate and salmeterol) Inhalation Powder,
a corticosteroid and long-acting β2-adrenergic agonist combination.
ArmonAir RespiClick (fluticasone propionate) Inhalation Powder,
an inhaled corticosteroid.
(Both approved 1/27/17, Teva Pharmaceuticals USA, Inc)
NOVEL SECONDARY HYPERPARATHYROIDISM CALCIMIMETIC: Parsabiv (etelcalcetide) Injection,
a calcium-sensing receptor agonist indicated for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis, the first therapy approved for this condition in 12 years. (Approved 2/7/17, Amgen Inc)
HOUSE DUST MITE ALLERGIES EVICTED: Odactra (house dust mite allergen extract) Sublingual Tablets,
a sublingual allergy immunotherapy tablet indicated as immunotherapy for house dust miteâ induced allergic rhinitis, with or without conjunctivitis, the first allergen extract to be administered under the tongue for this treatment. (Approved 3/1/17, ALK-Abelló A/S)
NEW OPTION FOR PLAQUE PSORIASIS: Siliq (brodalumab) Injection,
a human anti-interleukin-17-receptor monoclonal antibody for patients with moderate-to-severe plaque psoriasis. (Approved 2/15/17, Valeant Pharmaceuticals International, Inc)
ABUSE-DETERRENT OPIOIDS FOR SEVERE PAIN:
These extended-release tablets were approved for managing pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate:
Vantrela ER (hydrocodone bitartrate) Extended-Release Tablets,
an abuse-deterrent opioid formulation.
Arymo ER (morphine sulfate) Extended-Release Tablets,
an extended-release, abuse-deterrent, opioid analgesic formulation.
(Vantrela ER approved 1/17/17, Teva Pharmaceuticals USA, Inc; Arymo ER approved 1/9/17, Egalet Corporation)
VASOCONSTRICTOR FOR ACNE ROSACEA: Rhofade (oxymetazoline hydrochloride) Cream,
a topical α1A adrenoceptor agonist vasoconstrictor for treating persistent facial erythema associated with rosacea in adults, the first α1A adrenoceptor agonist approved for this condition. (Approved 1/18/17, Allergan, Inc)
Just shy of 3 months into the new year, the FDA has already granted a number of new drug approvals and new indications for drugs already approved. Scroll through the slides above for a look at some of the more significant recent approvals for primary care.For a quick review of last year’s approvals, go to Top 20 Primary Care Drugs Approved in 2016. SOURCESCenterWatch: 2016 FDA Approved DrugsDrugs.com: New Drug ApprovalsÂ
